Nurix Inc. announced the appointment of Dr. Nancy Pryer as the company’s chief development officer. Dr. Pryer will join Nurix’s executive management team to lead the company’s preclinical, translational and clinical drug development efforts. Dr. Pryer joins Nurix from BioMarin Pharmaceutical, where she served as vice president of translational sciences. In that role, she led the company’s efforts in biomarker discovery, bioanalytics, immunogenicity assessment and clinical pharmacology.